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Thymidine catabolism promotes 
NADPH oxidase-derived reactive 
oxygen species (ROS) signalling in 
KB and yumoto cells
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Thymidine phosphorylase (TP) is a rate-limiting enzyme in the thymidine catabolic pathway. TP is 
identical to platelet-derived endothelial cell growth factor and contributes to tumour angiogenesis. 
TP induces the generation of reactive oxygen species (ROS) and enhances the expression of oxidative 
stress-responsive genes, such as interleukin (IL)-8. However, the mechanism underlying ROS induction 
by TP remains unclear. In the present study, we demonstrated that TP promotes NADPH oxidase-
derived ROS signalling in cancer cells. NADPH oxidase inhibition using apocynin or small interfering 
RNAs (siRNAs) abrogated the induction of IL-8 and ROS in TP-expressing cancer cells. Meanwhile, 
thymidine catabolism induced by TP increased the levels of NADPH and intermediates of the pentose 
phosphate pathway (PPP). Both siRNA knockdown of glucose 6-phosphate dehydrogenase (G6PD), 
a rate-limiting enzyme in PPP, and a G6PD inhibitor, dihydroepiandrosterone, reduced TP-induced 
ROS production. siRNA downregulation of 2-deoxy-D-ribose 5-phosphate (DR5P) aldolase, which is 
needed for DR5P to enter glycolysis, also suppressed the induction of NADPH and IL-8 in TP-expressing 
cells. These results suggested that TP-mediated thymidine catabolism increases the intracellular 
NADPH level via the PPP, which enhances the production of ROS by NADPH oxidase and activates its 
downstream signalling.
Angiogenesis is a critical determinant of tumour growth and metastasis, as well as of wound healing, embryonic 
development, and arteriosclerosis1. We previously demonstrated that thymidine phosphorylase (TP), an enzyme 
that converts thymidine to thymine and 2-deoxy-D-ribose 1-phosphate, is identical to platelet-derived endothe-
lial cell growth factor (PD-ECGF), an angiogenic factor2, and that 2-deoxy-D-ribose (DR), a degradation product 
of thymidine produced by TP, also presents angiogenic activity3,4.
Previous findings indicate that TP is overexpressed in various cancer types and contributes to tumour 
angiogenesis3,5. The enzymatic activity of TP is essential for angiogenesis by TP6. Considering that inhibitors 
of TP activity could suppress angiogenesis, and consequently tumour growth and metastasis in TP-expressing 
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tumours, we developed a novel selective inhibitor of TP (TPI; 5-chloro-6-(2-iminopyrrolidin-1-yl) methyl-2,4 
(1 H,3 H)-pyrimidinedione hydrochloride; Ki = 2 × 10−8 M)7, which has several advantages over previously 
described inhibitors of TP. Using this TPI, we demonstrated that TP plays a key role in the invasiveness and metas-
tasis of TP-expressing solid tumours, and suggested that TPI may be an anti-metastatic agent for blood-borne 
metastasis8.
Both TP and DR are involved in the production of reactive oxygen species (ROS) and increase the secretion of 
stress-induced angiogenic cytokines, such as vascular endothelial growth factor (VEGF), matrix metalloprotein-
ase (MMP)-1, and interleukin (IL)-85,9,10. TP is expressed in numerous tumours; therefore, it may contribute to 
the progression of malignant tumours by generating oxidative stress3. Recently, we found that TP-mediated thy-
midine catabolism could supply the carbon source in glycolysis and the pentose phosphate pathway (PPP), thus 
contributing to cell survival under nutrient starvation11. However, the relationship between thymidine catabolism 
and oxidative stress remains unclear. In this study, we investigated the molecular basis for ROS generation by TP.
Results
Role of TP in ROS generation and IL-8 expression in human cancer KB cells. Previous findings 
suggested that TP induces oxidative stress and consequently enhances the expression of angiogenic factors, VEGF, 
MMP-1, and IL-8 in TP-overexpressing cells5,9,10. We also reported that the mRNA and protein levels of IL-8 in 
TP-overexpressing human epidermoid carcinoma KB (KB/TP) cells were higher than those in KB (KB/CV) cells 
that were transfected with control vector (CV)12.
First, we examined TP-induced ROS production and found that ROS levels in the absence and presence of 
500 μM thymidine in KB/TP cells were 3.1- and 4.4-fold higher than those in KB/CV cells, respectively (Fig. 1a). 
The ROS level increased with increasing concentrations of thymidine in KB/TP cells (Fig. 1b). To confirm 
whether TP-mediated ROS induces the expression of IL-8, KB/CV and KB/TP cells were treated with various 
concentrations of antioxidants, N-acetyl-L-cysteine (NAC) and EUK-8. IL-8 mRNA expression was higher in 
KB/TP cells than in KB/CV cells, and NAC and EUK-8 suppressed the enhanced expression of IL-8 mRNA in 
KB/TP cells in a dose-dependent manner (Fig. 1c). These results indicated that the ROS generated in KB/TP cells 
enhanced IL-8 mRNA transcription.
Role of NADPH oxidase in ROS generation by TP. ROS generated by NADPH oxidase stimulates 
diverse redox signalling pathways leading to angiogenesis and cell growth13,14. Therefore, we examined the effect 
of apocynin, an inhibitor of NADPH oxidase, on increased expression of heme oxygenase 1 (HO-1), a cellular 
oxidative stress marker, and IL-8 in KB/TP cells. Apocynin, at a concentration of 1 mM, suppressed the enhanced 
expression of HO-1 mRNA in KB/TP cells (Fig. 1d, left), suggesting that the augmented ROS level in KB/TP cells 
is generated by NADPH oxidase. Apocynin also suppressed IL-8 mRNA expression in KB/TP cells to the level 
observed in KB/CV cells (Fig. 1d, right).
Seven members of the NADPH oxidase family have been identified in mammalian species, each of which 
includes a different membrane-spanning catalytic subunit, NOX 1–5 and DUOX1 and 215,16. NOX1, 2, 4 and 5 
mRNAs were expressed, but NOX3, DUOX1, and DUOX2 mRNA expression was marginal in KB/CV and KB/
TP cells (Fig. 1e). Meanwhile, apocynin has been reported to inhibit NOX2-dependent superoxide production17. 
Therefore, we prepared siRNAs for NOX2 and p22phox, which are essential components of NOX2-containing 
NADPH oxidase, and down-regulated these genes to confirm the effect of apocynin. NOX2 and p22phox mRNA 
and protein expression levels were efficiently decreased by the siRNAs targeting NOX2 and p22phox, respec-
tively (Supplementary Fig. S1). ROS levels in KB/TP cells were significantly decreased by downregulation of 
NOX2 and p22phox (Fig. 1f). The expression levels of IL-8 mRNA in KB/TP cells in the absence and presence 
of thymidine were also considerably decreased by NOX2 and p22phox siRNAs (Fig. 1g). These results indicated 
that NOX2-containing NADPH oxidase is involved in ROS production in KB/TP cells. In addition to KB cells, 
we examined human cervical cancer Yumoto cells, which intrinsically express TP. We previously reported that 
TPI suppressed ROS level and IL-8 expression in Yumoto cells12. NAC also abrogated IL-8 expression in Yumoto 
cells12. The expression levels of NADPH oxidase isoforms in Yumoto cells were different from those in KB cells 
(Supplementary Fig. S2a). DUOX1 expression in Yumoto cells was higher than that in KB cells. Down-regulation 
of TP by a TP-targeting siRNA (Fig. 2b, left) suppressed the expression of IL-8, but not that of DUOX1 in Yumoto 
cells (Supplementary Fig. S2b). Furthermore, the attenuation of DUOX1 using a siRNA (Supplementary Fig. S2c) 
decreased the ROS levels (Supplementary Fig. S2d) and IL-8 expression (Supplementary Fig. S2e) in Yumoto cells. 
These data suggested that, as well as the TP-NOX2 signalling in KB cells, DUOX1 increased the levels of ROS and 
IL-8 in Yumoto cells.
Effect of TP on intracellular levels of NADPH. Levels of NADPH, a substrate for NADPH oxidase, 
increased with increasing concentrations of thymidine in KB/TP cells (Fig. 2a, left). NADPH levels in KB/TP 
cells were higher than those in KB/CV cells and in KB (KB/TPmut) cells, which express an enzymatically inac-
tive mutant TP (Fig. 2a, right). These findings suggested that NADPH levels were increased by TP, and that the 
enzyme activity is required for increased production of NADPH. Treatment of Yumoto cells with TP siRNA con-
siderably attenuated the expression of TP (Fig. 2b, left), and decreased the levels of NADPH and HO-1 mRNA to 
67 and 57% of those in control cells, respectively (Fig. 2b, middle and right).
NADPH is mainly generated during the oxidative phase of the PPP. Previous reports demonstrated that the 
suppression of glucose 6-phosphate dehydrogenase (G6PD), the first and rate-limiting enzyme of the PPP, atten-
uated NADPH oxidase-derived ROS generation in different cell types18–21. The expression levels of G6PD in KB/
TP cells were slightly lower than those in KB/CV cells (Fig. 2e). We examined the effect of dihydroepiandros-
terone (DHEA), an inhibitor of G6PD, on the enhanced ROS production in KB/TP cells. DHEA suppressed the 
levels of ROS (Fig. 2c) and HO-1 mRNA expression (Fig. 2d) in KB/TP cells, but did not affect the expression of 
www.nature.com/scientificreports/
3Scientific REPORTS |  (2018) 8:6760  | DOI:10.1038/s41598-018-25189-y
HO-1 in KB/CV and KB/TPmut cells (Fig. 2d). DHEA also decreased HO-1 expression in Yumoto cells (Fig. S2f). 
Furthermore, when the expression of G6PD was down-regulated in KB/CV and KB/TP cells (Fig. 2e), the levels 
of NADPH (Fig. 2f) and HO-1 mRNA expression (Fig. 2g) in KB/TP cells decreased. These results suggested that 
TP augmented NADPH levels through the oxidative phase of the PPP, which increased the generation of NADPH 
oxidase-derived ROS.
NADPH enhances NADPH oxidase-derived ROS generation, whereas it augments reduced glutathione (GSH) 
levels and suppresses the oxidative status in cells. We previously reported that expression of γ-glutamylcysteine 
synthetase (γ-GCS), a rate-limiting enzyme of glutathione synthesis, and the total glutathione level in KB/TP 
cells were significantly lower than those in KB/CV and KB/TPmut cells12. In this study, we evaluated the GSH 
level in KB/TP cells and found it to be lower than that in KB/CV cells, regardless of the NADPH levels in the cells 
(Supplementary Fig. S3). These results suggested that the generation of GSH is attenuated in KB/TP cells.
Figure 1. Involvement of NADPH oxidase in TP-induced ROS generation. (a) A representative sample for 
three independent FACS analyses is displayed (Left). Cells were treated with 500 μM thymidine for 48 h, and 
then ROS levels were measured in the cells. Proportions of cells in the M1 fraction are shown as relative levels 
of ROS. Relative ROS levels in KB/CV and KB/TP cells in the absence or presence of 500 μM thymidine are 
measured by using H2DCF-DA fluorescence dye (Right). (b) ROS levels in KB/CV and KB/TP cells incubated in 
the absence or presence of thymidine at 250 or 500 μM for 48 h. (c) Attenuated expression of IL-8 mRNA in KB/
TP cells treated with NAC (left) and EUK8 (right) for 48 h. Expression of IL-8 in KB/CV and KB/TP cells was 
determined by real-time PCR. (d) Decreased expression of HO-1 and IL-8 mRNAs in KB/TP cells treated with 
apocynin for 48 h. (e) Expression of NOX isoforms in KB cells. Expression levels of NOX isoforms in KB/CV 
and KB/TP cells were determined by real-time PCR. (f) The effect of down-regulation of NOX2 and p22phox on 
the production of ROS in KB/CV and KB/TP cells. The cells transfected with NOX2 siRNA or p22phox siRNA 
were treated with 10 μM H2DCF-DA for 1 h and ROS levels were determined by using FACScan. (g) KB cells 
transfected with NOX2 siRNA or p22phox siRNA were treated with or without 500 μM thymidine for 48 h and 
IL-8 mRNA expression levels were determined by real-time PCR. Data are presented as mean ± SD. ∗P < 0.01.
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Augmentation of PPP metabolites in KB/TP cells. We previously reported that thymidine catabo-
lism by TP can supply the carbon source in the glycolytic pathway and the PPP11. Figure 3a shows the catabolic 
pathway of thymidine. We investigated time-dependent changes in metabolite levels of the PPP in KB/TP cells 
using capillary electrophoresis time-of-flight mass spectrometry (CE-TOFMS) after the addition of thymidine. 
Intracellular levels of thymidine-derived DR5P increased and achieved peak levels 1 h after the addition of thy-
midine (Fig. 3a). The levels of PPP metabolites, ribulose-5-phosphate (Ru5P), ribose 5-phosphate (R5P), and 
5-phosphoribosyl 1α-diphosphate (PRPP), increased and achieved peaks at 3 h (Fig. 3a). Next, we examined the 
effect of silencing of 2-deoxy-D-ribose 5-phosphate aldolase (DERA), a key enzyme in the pathway by which 
thymidine-derived DR5P enters glycolysis and the PPP (Fig. 3a), on the levels of NADPH in KB/TP cells treated 
with thymidine. DERA siRNA suppressed NADPH in KB/TP cells (Fig. 3b). siRNAs against DERA and G6PD also 
decreased IL-8 expression (Fig. 3c). These results suggested that the augmentation of PPP flux by TP-mediated 
thymidine catabolism generated intracellular NADPH, which consequently was involved in the expression of IL-8 
in KB/TP cells (Fig. 4).
Figure 2. Effect of TP on Intracellular levels of NADPH (a) NADPH levels in KB/CV and KB/TP cells incubated 
in the absence or presence of thymidine at 250 or 500 μM for 48 h (left). Effect of TP activity on NADPH levels in 
KB cells. NADPH levels in KB/CV, KB/TP and KB/TPmut cells treated with or without 500 μM thymidine for 48 h 
were determined (right). NADPH levels in KB/CV and KB/TP cells were measured using a NADPH assay kit. (b) 
Effect of TP knockdown on TP mRNA (left), NADPH (middle), and HO-1 mRNA (right) levels in Yumoto cells. 
(c) ROS levels in KB/TP cells treated with DHEA for 24 h. (d) Expression levels of HO-1 mRNA were determined 
by real-time PCR in KB/CV, KB/TP, and KB/TPmut cells treated with DHEA for 48 h. (e) KB cells were transfected 
with G6PD siRNA or negative control siRNA. The levels of G6PD mRNA (upper) and G6PD protein (lower) were 
determined by real-time PCR and immunoblotting, respectively. (f) Effect of downregulation of G6PD on NADPH 
levels in KB cells. KB cells transfected with G6PD siRNAs were treated with 500 μM thymidine for 48 h, and 
NADPH intracellular levels were determined. (g) Effect of downregulation of G6PD on HO-1 mRNA levels in KB 
cells. Data are presented as mean ± SD. ∗P < 0.01, ∗∗P < 0.05.
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Discussion
When present in high quantities, ROS induce apoptosis and senescence; however, they function as signalling 
molecules at lower levels22. ROS are generated in many tumours and are involved in tumour angiogenesis23. 
ROS can be generated from several sources, such as the mitochondrial electron transport system, cytochrome 
p450, uncoupled NO synthase (NOS), xanthine oxidase, and NADPH oxidase. Among them, NADPH oxi-
dase is the only known mammalian enzyme system dedicated to the production of ROS alone. ROS generated 
by NADPH oxidase participate in intracellular signalling pathways that regulate the proliferation of vascular 
and non-vascular cells24,25. NADPH oxidases have specific subcellular localisations. Spatially confined ROS 
Figure 3. Levels of PPP intermediates in KB/TP cells after addition of thymidine. (a) KB/TP were incubated in 
serum-free medium with 500 μM thymidine for the indicated times, and levels of metabolites were determined 
using CE-TOFMS. (b) KB cells transfected with DERA siRNA were treated with 500 μM thymidine for 48 h 
and the intracellular levels of NADPH were determined. (c) Effect of DERA and G6PD downregulation on IL-8 
mRNA levels in KB/TP cells. Data are presented as mean ± SD. ∗P < 0.01.
Figure 4. Schematic representation of the molecular mechanism underlying TP-induced ROS production.
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production in close proximity to redox-sensitive targets may permit ROS to activate specific redox signalling 
pathways. NADPH oxidase-derived ROS were previously suggested to increase cell growth by direct activation 
of certain oxidative-response transcription factors including nuclear factor kappaB (NFκB)26. We also found that 
ROS generated in TP-expressing KB cells activated canonical NFκB signalling and enhanced the expression of 
genes regulated by NFκB27.
We assumed that TP is involved in some mechanisms for ROS production and their mechanistic dominance 
differs depending on cell type or nutrient status. Brown et al. demonstrated that TP induced expression of an 
oxidative stress marker HO-1 in human colon carcinoma cells (Colo320 cells) and human urinary bladder carci-
noma cells (RT112 cells), and discussed that the DR generated by TP during thymidine catabolism may contrib-
ute to ROS production by finally being converted to enediol via schiff base reactions9. Additionally, we and other 
group reported that TP suppresses the synthesis of glutathione, leading to the increase in ROS production12,28. In 
this paper, we also reported that TP contributed to enhance ROS level via NADPH oxidase.
To examine the effect of thymidine in KB/TP cells, the cells were treated with 250 or 500 μM thymidine; the 
results are shown in Figs 1a,b,g, 2a,f and 3a,b. The levels of thymidine used in the in vitro experiments were higher 
than those in sera. However, in a specific region of the tumour, such as a necrotic area, the thymidine level might 
be considerably elevated, because DNA of necrotic cells is degraded and supplies a large amount of thymidine9. 
Even in normal cell culture conditions without supplemental thymidine, levels of ROS, HO-1, IL-8, and NADPH 
in KB/TP were higher than those in KB/CV (Figs 1a,d and 2a). Therefore, we consider that TP signalling func-
tions at physiological thymidine concentrations.
NADPH has a dual effect, oxidative and anti-oxidative. NADPH is a substrate for NADPH oxidase that gen-
erates ROS, whereas it augments GSH, which serves as the intracellular anti-oxidant. The NADPH level in KB/
TP cells was higher than that in KB/CV cells, while the GSH level in KB/TP cells was lower than that in KB/CV 
cells (Supplementary Fig. S3). Our previous findings suggested that TP-mediated thymidine catabolism lead to 
the decrease in γ-GCS and glutathione levels in KB cells12. The decrease in the level of total glutathione in KB/
TP cells may be the cause of the low levels of NADPH-induced GSH in KB/TP cells. These results suggest that 
NADPH in KB/TP cells is preferentially utilised by NADPH oxidase rather than glutathione reductase which 
generates GSH (Fig. 4).
Alternatively, some papers reported the pro-oxidative effect of NADPH oxidase, which is induced by NFκB 
transcriptional activation29–31. Expression of NADPH oxidase subunit p22phox was increased by NFκB in aortic 
smooth muscle and pancreatic cancer cells32,33. We also demonstrated that TP induced the activation of NFκB in 
KB and Yumoto cells27 and found that expression of p22phox in KB/TP cells was higher than that in KB/CV cells 
(Supplementary Fig. S1). NFκB activation in TP-expressing cells was suppressed by antioxidants27, suggesting 
that the relationship between NADPH oxidase-generated ROS and NFκB activation comprises positive feedback 
with each other. Further studies are needed to clarify this relationship in TP-expressing cancer cells.
In this study, we demonstrated that TP elevates the intracellular levels of NADPH generated in the PPP, 
which enhances the production of ROS by NADPH oxidase. ROS consequently induces the expression of IL-8, a 
pro-angiogenic factor (Fig. 4).
Methods
Chemicals and cell culture. NAC was obtained from Sigma-Aldrich (St. Louis, MO, USA). Apocynin 
and EUK-8 were obtained from Calbiochem (San Diego, CA, USA). 2′,7′-dichlorodihydrofluorescein diacetate 
(H2DCF-DA) was obtained from Molecular Probes (Eugene, OR, USA). Human epidermoid carcinoma KB and 
human cervical carcinoma Yumoto cells were grown in Dulbecco’s modified Eagle’s medium (DMEM, Nissui 
Seiyaku, Tokyo, Japan) containing 10% foetal bovine serum, 2 mM glutamine, and 100 units/mL of penicillin 
at 37 °C in a 5% CO2 humidified atmosphere. The medium was changed to fresh serum-free medium before the 
experiments.
Transfection of TP/PD-ECGF cDNA into KB cells. We previously established the following stable cell 
lines: KB/CV, KB/TP, and KB/TPmut10. The TP/PD-ECGF full-length cDNA plasmid, TP/PD-ECGF mutant 
plasmid (L148R, Leu-148→Arg)6, or the empty vector was transfected into KB cells by electroporation34. After 
selection with geneticin, the expression of TP in each clone was determined by immunoblotting analysis using 
an anti-TP monoclonal antibody, as previously described35. ATP-positive clone (KB/TP cells) and a control 
vector-transfected clone (KB/CV cells) were used for further analysis.
Real-time PCR analysis. Real-time PCR analysis was conducted as previously described27. Quantitative 
measurements were determined using the ΔΔCt method, and glyceraldehyde-3-phosphate (GAPDH) expression 
was used as the internal control. The primers for real-time PCR are described in Table S1.
Immunoblotting analysis. Immunoblotting analysis was performed as previously described12. Primary 
antibodies against DUOX1 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), G6PD (Sigma-Aldrich), β-Actin 
(Santa Cruz Biotechnology), and horseradish peroxidase-conjugated secondary antibodies (GE Healthcare, 
Buckinghamshire, UK) were used.
NADPH assay. NADPH levels were determined by using EnzyChrom™ NADP+/NADPH assay kit (BioAssay 
Systems, Hayward, CA, USA) following the manufacturer’s instructions.
GSH assay. GSH levels were measured by using the Glutathione (GSH/GSSG/Total) Fluorometric Assay Kit 
(BioVision, Milpitas, CA, USA) following the manufacturer’s instructions.
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RNA interference. NOX2, p22phox, and G6PD siRNA duplexes were synthesised in vitro by a Silencer™ 
siRNA construction kit (Thermo Fisher Scientific, Waltham, MA, USA) following the manufacturer’s instruc-
tions. TP, DERA, DUOX1, and negative control siRNA duplexes were purchased from Sigma. Depletion of DERA 
was conducted as previously described11. Cells were transfected with the siRNAs using Lipofectamine RNAiMAX 
(Thermo Fisher Scientific) following the manufacturer’s instructions.
Measurement of cellular ROS level. ROS production was measured using H2DCF-DA, an uncharged 
cell-permeable fluorescent probe. Cells were treated with H2DCF-DA (10 μM), washed, re-suspended in phos-
phate buffered saline and analysed using FACScan (FACSCalibur, BD Bioscience, San Jose, CA, USA) as described 
previously36.
Metabolite quantification of KB cells using CE-TOFMS. Intracellular metabolites were measured by 
CE-TOFMS (Agilent Technologies, Santa Clara, CA, USA) as previously described37. The data obtained were ana-
lysed using MasterHands38. The metabolite identities were determined by matching their m/z values and migra-
tion times with those of their standard compounds.
Statistical analysis. Statistical analysis was conducted as previously described12. Results were statistically 
analysed using GraphPad prism v5.0 software. Statistical analyses for all experiments including more than two 
groups were performed by using one-way analysis of variance (ANOVA). Student’s t tests were used for exper-
iments including two groups. Data are presented as means ± SD. The differences were considered statistically 
significant at P < 0.05.
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